Opinion|Videos|November 25, 2024
VMS Symptoms and Neurokinin Receptor Antagonists
Panelists discuss how neurokinin 3 (NK3) receptors contribute to vasomotor symptoms (VMS) and how antagonism of NK3 receptors with drugs like fezolinetant can effectively reduce VMS, while also exploring the dual receptor action of elinzanetant, which blocks both NK1 and NK3 receptors to improve VMS and associated sleep disturbances.
Advertisement
Episodes in this series
- What are neurokinin 3 (NK3) receptors, and how can antagonism of NK3 receptors affect VMS?
- What is fezolinetant?
Note: The binding affinity of fezolinetant at NK3 receptors is 450 times greater than those for neurokinin 1 (NK1); this is an NK3 and has no NK1 action
- What is elinzanetant?
Note: Elinzanetant is currently under review with the FDA
- How can blockade of NK1 and NK3 receptors improve VMS and sleep disturbances associated with menopause?
Advertisement
Related to this article
Blood levels alone cannot confirm safe testosterone dosing. Asking about androgenic effects and allowing months for response are central to care.
A global consensus defines what the evidence supports for testosterone in women. Benefits for strength, mood, and cognition lack randomized data.
A testosterone patch improved sexual desire in trials but never won US approval. Normal female physiology defines what replacement should target.
The WHI never studied testosterone, yet it chilled conversations about every hormone, with lasting consequences for women’s sexual health.
As estrogen came to define menopause care, testosterone faded from view, and the oral combination clinicians relied on was never FDA approved.
Androgen therapy for women predates the headlines by decades. Early research showed promise for desire, but long-term safety data never caught up.
Liudmila Zhaunova on a global Flo app study linking higher physical activity to lower perimenopause symptom burden.
The 16-item Perimenopause Symptom Scale showed strong reliability and validity among 1255 women aged 35 to 59 years in the United States.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
What biomarker-guided preeclampsia care could look like
2
Testosterone for women: Global consensus and physiologic dosing
3
Testosterone physiology in women and the long road to approval
4
Testosterone in women: Androgenic adverse events and lab monitoring
5